AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer

AstraZeneca plc AZN and Daiichi Sankyo Co Ltd DSKYF have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu.
The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy.
Enhertu demonstrated superiority in progression-free survival (PFS) over Roche Holdings AG’s RHHBY Kadcyla (trastuzumab emtansine) and chemo.
Complete data aren’t available yet, but Daiichi Sankyo noted the trial had been recommended for unblinding by the Independent Data Monitoring Committee (IDMC) after reaching this interim analysis.
The companies also said that while overall survival data showed a “strong trend” toward improvement over the control, the OS data haven’t matured enough to conclude anything.
Price Action: DSKYF shares are down 2.65% at $17.61, while AZN stock is up 0.43% at $56.60 during the market session on the last check Monday.